Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition

BMC Cancer

Gaofeng Xiong³  Lei Deng³  Jieqing Zhu³  Piotr G Rychahou²  Ren Xu¹ 

[1] Department of Molecular and Biomedical Pharmacology, University of Kentucky, 741 S. Limestone, BBSRB, Lexington, KY 40536, USA

[2] Department of Surgery, University of Kentucky, Lexington, KY 40536, USA

[3] Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA

关键词: Cell proliferation;    Cancer progression;    Collagen deposition;    Breast cancer;    Tumor microenvironment;   

Others  :  859172
DOI  :  10.1186/1471-2407-14-1

 received in 2013-09-27, accepted in 2013-12-26,  发布年份 2014

【 摘 要 】

Background

Increased collagen deposition provides physical and biochemical signals to support tumor growth and invasion during breast cancer development. Therefore, inhibition of collagen synthesis and deposition has been considered a strategy to suppress breast cancer progression. Collagen prolyl-4-hydroxylase α subunit 2 (P4HA2), an enzyme hydroxylating proline residues in -X-Pro-Gly- sequences, is a potential therapeutic target for the disorders associated with increased collagen deposition. However, expression and function of P4HA2 in breast cancer progression are not well investigated.

Methods

Gene co-expression analysis was performed in the published microarray datasets to identify potential regulators of collagen I, III, and IV in human breast cancer tissue. Expression of P4HA2 was silenced by shRNAs, and its activity was inhibited by 1, 4-DPCA, a prolyl-4-hydroxylase inhibitor. Three-dimensional culture assay was used to analyze roles of P4HA2 in regulating malignant phenotypes of breast cancer cells. Reduced deposition of collagen I and IV was detected by Western blotting and immunofluorescence. Control and P4HA2-silenced breast cancer cells were injected into fat pad and tail vein of SCID mice to examine effect of P4HA2 on tumor growth and lung metastasis.

Results

Using gene co-expression analysis, we showed that P4HA2 was associated with expression of Col1A1, Col3A1, and Col4A1 during breast cancer development and progression. P4HA2 mRNA levels were significantly upregulated in breast cancer compared to normal mammary tissue. Increased mRNA levels of P4HA2 correlated with poor clinical outcome in breast cancer patients, which is independent of estrogen receptor status. Silencing P4HA2 expression or treatment with the P4HA inhibitor significantly inhibited cell proliferation and suppressed aggressive phenotypes of breast cancer cells in 3D culture, accompanied by reduced deposition of collagen I and IV. We also found that knockdown of P4HA2 inhibited mammary tumor growth and metastasis to lungs in xenograft models.

Conclusion

These results suggest the critical role of P4HA2 in breast cancer progression and identify P4HA2 as a potential therapeutic target and biomarker for breast cancer progression.

【 授权许可】

   
2014 Xiong et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Bissell MJ, Hines WC: Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011, 17(3):320-329.
• [2]Lu P, Weaver VM, Werb Z: The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196(4):395-406.
• [3]Muschler J, Streuli CH: Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harbor Perspect Biol 2010, 2(10):a003202.
• [4]Lochter A, Bissell MJ: Involvement of extracellular matrix constituents in breast cancer. Semin Cancer Biol 1995, 6(3):165-173.
• [5]Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ: Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006, 4(1):38. BioMed Central Full Text
• [6]Canty EG, Kadler KE: Procollagen trafficking, processing and fibrillogenesis. J Cell Sci 2005, 118(Pt 7):1341-1353.
• [7]Pozzi A, Wary KK, Giancotti FG, Gardner HA: Integrin alpha1beta1 mediates a unique collagen-dependent proliferation pathway in vivo. J Cell Biol 1998, 142(2):587-594.
• [8]Yeh YC, Lin HH, Tang MJ: A tale of two collagen receptors, integrin beta1 and discoidin domain receptor 1, in epithelial cell differentiation. Am J Physiol Cell Physiol 2012, 303(12):C1207-C1217.
• [9]Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW, Keely PJ, Longmore GD: The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat Cell Biol 2013, 15(6):677-687.
• [10]Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ: Collagen density promotes mammary tumor initiation and progression. BMC Med 2008, 6:11. BioMed Central Full Text
• [11]Shields MA, Dangi-Garimella S, Krantz SB, Bentrem DJ, Munshi HG: Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem 2011, 286(12):10495-10504.
• [12]Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, et al.: Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005, 115(5):1163-1176.
• [13]Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et al.: Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139(5):891-906.
• [14]Van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
• [15]Condeelis J, Segall JE: Intravital imaging of cell movement in tumours. Nat Rev Cancer 2003, 3(12):921-930.
• [16]Myllyharju J: Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol 2003, 22(1):15-24.
• [17]Gorres KL, Raines RT: Prolyl 4-hydroxylase. Crit Rev Biochem Mol Biol 2010, 45(2):106-124.
• [18]Kukkola L, Hieta R, Kivirikko KI, Myllyharju J: Identification and characterization of a third human, rat, and mouse collagen prolyl 4-hydroxylase isoenzyme. J Biol Chem 2003, 278(48):47685-47693.
• [19]Pajunen L, Jones TA, Helaakoski T, Pihlajaniemi T, Solomon E, Sheer D, Kivirikko KI: Assignment of the gene coding for the alpha-subunit of prolyl 4-hydroxylase to human chromosome region 10q21.3-23.1. Am J Hum Genet 1989, 45(6):829-834.
• [20]Annunen P, Helaakoski T, Myllyharju J, Veijola J, Pihlajaniemi T, Kivirikko KI: Cloning of the human prolyl 4-hydroxylase alpha subunit isoform alpha(II) and characterization of the type II enzyme tetramer: the alpha(I) and alpha(II) subunits do not form a mixed alpha(I)alpha(II)beta2 tetramer. J Biol Chem 1997, 272(28):17342-17348.
• [21]Sundberg C, Ivarsson M, Gerdin B, Rubin K: Pericytes as collagen-producing cells in excessive dermal scarring. Lab Invest 1996, 74(2):452-466.
• [22]Stephens EH, Grande-Allen KJ: Age-related changes in collagen synthesis and turnover in porcine heart valves. J Heart Valve Dis 2007, 16(6):672-682.
• [23]Bulleid NJ, John DC, Kadler KE: Recombinant expression systems for the production of collagen. Biochem Soc Trans 2000, 28(4):350-353.
• [24]Nokelainen M, Nissi R, Kukkola L, Helaakoski T, Myllyharju J: Characterization of the human and mouse genes for the alpha subunit of type II prolyl 4-hydroxylase: identification of a previously unknown alternatively spliced exon and its expression in various tissues. Eur J Biochem 2001, 268(20):5300-5309.
• [25]Grimmer C, Balbus N, Lang U, Aigner T, Cramer T, Muller L, Swoboda B, Pfander D: Regulation of type II collagen synthesis during osteoarthritis by prolyl-4-hydroxylases: possible influence of low oxygen levels. Am J Pathol 2006, 169(2):491-502.
• [26]Myllyharju J, Schipani E: Extracellular matrix genes as hypoxia-inducible targets. Cell Tissue Res 2010, 339(1):19-29.
• [27]Chang KP, Yu JS, Chien KY, Lee CW, Liang Y, Liao CT, Yen TC, Lee LY, Huang LL, Liu SC, et al.: Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J Proteome Res 2011, 10(11):4935-4947.
• [28]Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, et al.: Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 2005, 65(4):1587-1597.
• [29]Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, Jones A, Simpson P, Harris RA, Jat PS, Neville AM, et al.: cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 2003, 22(17):2680-2688.
• [30]Pan PW, Zhang Q, Bai F, Hou J, Bai G: Profiling and comparative analysis of glycoproteins in Hs578BST and Hs578T and investigation of prolyl 4-hydroxylase alpha polypeptide II expression and influence in breast cancer cells. Biochemistry (Mosc) 2012, 77(5):539-545.
• [31]Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ: Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 1992, 89(19):9064-9068.
• [32]Xu R, Nelson CM, Muschler JL, Veiseh M, Vonderhaar BK, Bissell MJ: Sustained activation of STAT5 is essential for chromatin remodeling and maintenance of mammary-specific function. J Cell Biol 2009, 184(1):57-66.
• [33]Gilkes DM, Chaturvedi P, Bajpai S, Wong CC, Wei H, Pitcairn S, Hubbi ME, Wirtz D, Semenza GL: Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res 2013, 73(11):3285-3296.
• [34]Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010, 123(3):725-731.
• [35]Xu R, Mao JH: Gene transcriptional networks integrate microenvironmental signals in human breast cancer. Integr Biol: Quant Biosci Nano macro 2011, 3(4):368-374.
• [36]Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et al.: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10(6):529-541.
• [37]Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, et al.: Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 2008, 14(17):5555-5564.
• [38]Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-679.
• [39]Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, et al.: The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007, 1(1):84-96.
• [40]Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, Bissell MJ: Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 1998, 95(25):14821-14826.
• [41]Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ: Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997, 137(1):231-245.
• [42]Salic A, Mitchison TJ: A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA 2008, 105(7):2415-2420.
• [43]Xiong G, Wang C, Evers BM, Zhou BP, Xu R: RORalpha suppresses breast tumor invasion by inducing SEMA3F expression. Cancer Res 2012, 72(7):1728-1739.
• [44]Franklin TJ, Morris WP, Edwards PN, Large MS, Stephenson R: Inhibition of prolyl 4-hydroxylase in vitro and in vivo by members of a novel series of phenanthrolinones. Biochem J 2001, 353(Pt 2):333-338.
• [45]Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, et al.: Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 2010, 9(17):3515-3533.
• [46]Sondo E, Tomati V, Caci E, Esposito AI, Pfeffer U, Pedemonte N, Galietta LJ: Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am J Physiol Cell Physiol 2011, 301(4):C872-C885.
• [47]Li Q, Chow AB, Mattingly RR: Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors. J Pharmacol Exper Ther 2010, 332(3):821-828.
• [48]Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS: Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21(2):227-239.
• [49]Pickl M, Ries CH: Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009, 28(3):461-468.
• [50]Spencer VA, Xu R, Bissell MJ: Extracellular matrix, nuclear and chromatin structure, and gene expression in normal tissues and malignant tumors: a work in progress. Adv Cancer Res 2007, 97:275-294.
• [51]Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G, et al.: Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 2013, 15(6):637-646.
• [52]Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massague J: Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011, 17(7):867-874.
• [53]El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, Csizmadia E, Mariani O, Zhu C, Campagne A, et al.: Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci USA 2012, 109(43):17460-17465.
• [54]Brownfield DG, Venugopalan G, Lo A, Mori H, Tanner K, Fletcher DA, Bissell MJ: Patterned collagen fibers orient branching mammary epithelium through distinct signaling modules. Curr Biol 2013, 23(8):703-709.
• [55]Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D, Semenza GL: Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem 2013, 288(15):10819-10829.